TWI291952B - Purification of lipstatin - Google Patents

Purification of lipstatin Download PDF

Info

Publication number
TWI291952B
TWI291952B TW89102668A TW89102668A TWI291952B TW I291952 B TWI291952 B TW I291952B TW 89102668 A TW89102668 A TW 89102668A TW 89102668 A TW89102668 A TW 89102668A TW I291952 B TWI291952 B TW I291952B
Authority
TW
Taiwan
Prior art keywords
extraction
polar solvent
ribastatin
heptane
water
Prior art date
Application number
TW89102668A
Other languages
Chinese (zh)
Inventor
Doswald Stephan
Kupfer Ernst
Steeinbauer Gerhard
Steinwender Erich
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to TW89102668A priority Critical patent/TWI291952B/en
Application granted granted Critical
Publication of TWI291952B publication Critical patent/TWI291952B/en

Links

Description

1291952 五、發明說明(1) '~〜----一· | 本&明係有關一種純化里卜斯他丁之方法。更特定言 I 本發明係有關一種由雙流向萃取法形式之液體-液體 I卒取法與逆流萃取法形式之再萃取法組合之方法,作為自 里卜斯他丁粗產物中單離出驚人高收率與高純度之里卜斯 i他丁之方法。 | 里卜斯他丁為製備四氫里卜斯他丁(THL,歐斯他 丨(Or listat))時之相當重要之關鍵中間物,其適用於預防 |及治療與肥胖有關之疾病。 里卜斯他丁,其醱酵製法,其自微生物之單離法及其形 丨成四氫里卜斯他丁之氫化法係已知者,且說明於例如:美 丨國專利案No. 4, 5 98, 08 9。 里卜斯他丁如下式:1291952 V. INSTRUCTIONS (1) '~~----一· | Ben & Ming is a method for purifying ribastatin. More specifically I The present invention relates to a method for combining a liquid-liquid I stroke method in the form of a dual flow extraction method with a re-extraction method in the form of a countercurrent extraction method, as a single high separation from the crude product of ribavirin The method of yield and high purity of Ribs i. Ribsstatin is a key intermediate in the preparation of tetrahydroribastatin (THL, Or listat), which is suitable for the prevention and treatment of diseases associated with obesity. Ribsstatin, its mashing method, known from the microbial isolation method and its hydrogenation method of tetrahydroribastatin, is described, for example, in the US Patent No. 4, 5 98, 08 9. Ribsstatin is as follows:

一種製備里卜斯他丁粗產物之方法亦說明於歐洲專利申 請案N 〇 · 9 6 1 0 6 5 9 8。此方法包括由放線菌綱微生物,例 如:毒三素鏈黴菌(Streptomyces toxytricini)進行好氣 性培養,其在實質上不含脂肪與油且包含合適碳與氣源、^ 無機鹽之水性介質中產生里卜斯他丁,直到初生長期@ 上已結束,且已產生足量細胞質量為止。然後在營養液中 1291952 五、發明說明(2) 一起添加亞油酸及抗氧化劑,及提需要選用之辛酸,,及N -甲醯基-L-白胺酸,或最好添加L—白胺酸。醱酵完成後, 萃取醱酵液。產生之里卜斯他丁粗產生可再經濃縮與純 化,例如:利用美國專利案肋· 4, 5 98, 〇89所述之層析法。 先前技藝中用於純化里卜斯他丁粗產物之方法之特徵為 利用多段式層析法或液體—液體萃取法來提高里卜斯他丁 濃度’組合多段式層析法來製得純里卜斯他丁。此等方法 典型地適用於依實驗室規模單離醱酵代謝物。然而,此等 方法通常不適合經濟型之大規模製法。A method for preparing a crude product of ribavirin is also described in the European patent application N 〇 · 9 6 1 0 6 5 9 8 . The method comprises aerobic culture by an actinomycete microorganism, such as Streptomyces toxytricini, which is produced in an aqueous medium substantially free of fats and oils and comprising a suitable carbon and gas source, and an inorganic salt. Ribsstatin, until the beginning of the long-term @ is over, and has produced sufficient cell quality. Then in the nutrient solution 12919952 5, invention instructions (2) together add linoleic acid and antioxidants, and need to choose the octanoic acid, and N-methyl decyl-L-leucine, or preferably add L-white Amino acid. After the fermentation is completed, the fermentation broth is extracted. The resulting crude production of ribastatin can be further concentrated and purified, for example, by the chromatography described in U.S. Patent No. 4, 5 98, 〇89. The prior art method for purifying the crude product of ribavirin is characterized by using multi-stage chromatography or liquid-liquid extraction to increase the concentration of ribsstatin' combined multi-stage chromatography to produce pure lining. Bustin. These methods are typically applied to isolate the lysate metabolites on a laboratory scale. However, these methods are generally not suitable for economical large-scale production.

曾有人試圖利用蒸餾法純化里卜斯他丁粗產物,但沒有 成功。里卜斯他丁在60 t下可保持數小時安定性,但由於 ,蒸汽壓低(7x W毫巴),因此無法在此溫度下進行真空 务餾(小於2 *巴)。在更高溫度下,1卜斯他丁則釋出二 氧化碳而降解。 里卜斯他丁粗產物亦可由 晶而純化。然而,卻需要高 且結晶產量極度依賴里卜斯 卜斯他丁粗產物品質低時, 產量亦低。 里卜斯他在-2 0 °C以下溫度結 成本之低溫結晶法技術設備, 化丁粗產物之品質。尤其當里 利用結晶法得到之里卜斯他丁 本發明提供一種新穎、簡單 斯他丁粗產物中純化出高收量 使粗產物品質低亦然。 本發明自里卜斯他丁粗產物 括: 且低成本之方法,可自里卜 與南純度之里卜斯他丁,即 中純化里卜斯他丁之方法包Attempts have been made to purify the crude ribavirin by distillation, but it has not been successful. Ribstatin maintains several hours of stability at 60 t, but because of the low vapor pressure (7 x W mbar), vacuum distillation (less than 2 * bar) cannot be performed at this temperature. At higher temperatures, 1 statin releases carbon dioxide and degrades. The crude ribastatin product can also be purified by crystals. However, it is required to be high and the crystallization yield is extremely dependent on the low quality of the crude ribavirin product, and the yield is also low. Ribs's low temperature crystallization technology equipment at a temperature below -200 °C, the quality of the crude product. In particular, the ribastatin obtained by the crystallization method provides a novel, simple statin crude product which has a high yield and a low quality of the crude product. The invention is based on the crude product of ribastatin: and the method of low cost, which can be used for purifying ribastatin from ribb and southern purity.

第5頁 1291952 五、發明說明(3) a)利用液體-液體萃取法,自選自:脂系或芳香系烴之 非極性溶劑中萃取里卜斯他丁至選自:羧酸、醇、0-單取 代之單或募乙二醇、二元醇或雙極性之非質子性溶劑之極 丨性溶劑中,然後 I b)加水稀釋極性溶劑相,或改變兩相比例,並再萃取 !里卜斯他丁至新鮮非極性溶劑中。 下列定義係說明及界定本文中說明本發明時所採用之各 種不同名詞之意義與範圍。 "雙流向萃取法’’指兩種溶劑之逆流萃取法。此萃取法之 i進-行方式如下圖: | —►輕相出口 (殘液)+雜質. I 萃取區 萃取溶劑 進料 洗滌區 洗蘇溶劑 ——►重相出口(萃液) 在萃取單位之頂部與底部引進兩種互溶性低之溶劑。待 分離之混合物(進料)則可在任一處送入,但若與洗滌溶劑 組合送入時,則最好在萃取單位的中段送入。上圖中,所 1291952 五、發明說明(4) 進行萃取法之萃取溶劑及萃液分別含有較高密度之、溶 i (重相),而洗務溶劑與殘液則分別含有較低密度之溶 !(輕相)。 ! ”逆流萃取法π —詞指待萃取之物質(進料)與要使用 種溶劑共同添加。此時,自待純化之化合物中分離之 量不如雙流向萃取法,因為省略了洗滌區。 逆流萃取法之進行方式如下圖: ——►輕相出口 (萃液) 進料+溶劑—— 萃取溶劑-η_ ——►重相出口(殘液) 在萃取單位頂部與底部分別送入一種溶劑加進料及 種互溶性低之溶劑。在一端出口之萃取溶劑富含目標 流出管柱(萃液)。在另一端出口則將用來送入進料後 出目標物質之溶劑(殘液)送出管柱。上圖中說明之萃 式為進料與殘液分別包含高密度溶劑(重相),而萃取 劑與萃液則分別包含低密度溶劑(輕相)。 劑 劑 之一 殘質 另一 物質| 被萃 取形 用溶 1291952 五、發明說明(5) π里卜斯他丁粗產物” 一詞指由醱酵過程分離細胞·生質, 萃取及濃縮後得到含里卜斯他丁與雜質之粗產物。 | 本發明係有關組合兩種液體-液體萃取法之方法,作為 自里卜斯他丁粗產物中分離出高純度與實際上全收量之里 卜斯他丁。Page 5 1291952 V. Description of the invention (3) a) Extraction of ribastatin from a non-polar solvent selected from the group consisting of: aliphatic or aromatic hydrocarbons by liquid-liquid extraction to: carboxylic acid, alcohol, 0 - single-substituted single or aromatic solvent in the presence of ethylene glycol, glycol or bipolar aprotic solvent, then I b) dilute the polar solvent phase with water, or change the two ratios and re-extract! Bustastatin to fresh non-polar solvents. The following definitions are intended to illustrate and define the meaning and scope of the various terms used in the description of the invention herein. "Double flow extraction method' refers to a countercurrent extraction of two solvents. The extraction method of this extraction method is as follows: | — ► light phase outlet (residual liquid) + impurity. I extraction zone extraction solvent feed washing zone scrubbing solvent - ► heavy phase outlet (extraction) in the extraction unit Two solvents with low miscibility are introduced at the top and bottom. The mixture to be separated (feed) can be fed at any point, but if it is fed in combination with the washing solvent, it is preferably fed in the middle of the extraction unit. In the above figure, 12919952 5. Inventive Note (4) The extraction solvent and extract of the extraction method contain higher density, soluble i (heavy phase), while the washing solvent and the residual liquid respectively contain lower density. Dissolve! (light phase). "Countercurrent extraction method π - word means that the substance to be extracted (feed) is added together with the solvent to be used. At this time, the amount of the compound to be purified is not as good as the double flow direction extraction method because the washing zone is omitted. The extraction method is carried out as follows: ——►light phase outlet (extraction) feed + solvent - extraction solvent - η_ ——► heavy phase outlet (residual liquid) A solvent is added to the top and bottom of the extraction unit. Feeding and solvent with low miscibility. The extraction solvent at one end is rich in the target outflow column (extract). At the other end, the solvent (residual) for sending the target substance after feeding is sent out. The column is characterized by a high-density solvent (heavy phase) for the feed and the raffinate, and a low-density solvent (light phase) for the extractant and the extract, respectively. A substance | extracted form used to dissolve 1291952 5, invention description (5) π ribs statin crude product" The term refers to the separation of cells from the fermentation process, biomass, extraction and concentration to obtain ribavirin and The crude product of impurities. The present invention relates to a method of combining two liquid-liquid extraction methods for separating high-purity and virtually all-receiving ribastatin from the crude ribavirin product.

通常,自里卜斯他丁粗產物中純化里卜斯他丁之方法包 括一種液體-液體萃取法,其係自選自脂系或芳香系烴之 非極性溶劑中萃取里卜斯他丁至選自羧酸、醇、0-單取代 之單或寡乙二醇、二元醇或雙極性非質子性溶劑之極性溶 劑中,然後加水稀釋極性溶劑相,或改變兩相比例,並再 !萃取里卜斯他丁至新鮮之非極性溶劑中。 | i 液體-液體萃取法係於下列溶劑系統中進行:非極性溶劑 丨選自:脂系或芳香系烴。較佳脂系烴為(:5-(:8脂系烴;更佳 丨為<:6-(:7脂系烴如:己烷或庚烷。芳香烴可選自苯,其可視 :需要經1至3個甲基取代。較佳芳香烴為苯與甲苯。 極性溶劑可選自:羧酸,例如:甲酸或q -C3烷基羧酸,In general, the method for purifying ribavirin from a crude ribastatin product comprises a liquid-liquid extraction method for extracting ribastatin from a non-polar solvent selected from a lipid or an aromatic hydrocarbon. From a polar solvent of a carboxylic acid, an alcohol, a 0-monosubstituted mono or oligoethylene glycol, a glycol or a bipolar aprotic solvent, then dilute the polar solvent phase with water, or change the two ratios, and again! Ribastatin is added to fresh, non-polar solvents. | i Liquid-liquid extraction is carried out in the following solvent systems: Non-polar solvents 丨 are selected from: aliphatic or aromatic hydrocarbons. Preferred aliphatic hydrocarbons are (: 5-(:8 aliphatic hydrocarbons; more preferably &::6-(:7 aliphatic hydrocarbons such as hexane or heptane. The aromatic hydrocarbons may be selected from benzene, which are visible: It is required to be substituted with 1 to 3 methyl groups. Preferred aromatic hydrocarbons are benzene and toluene. The polar solvent may be selected from a carboxylic acid such as formic acid or q-C3 alkyl carboxylic acid.

如:乙酸或丙酸,或醇,如:曱醇、乙醇、丙醇、或0-:單取代之單或寡乙二醇,如:乙二醇單甲醚或(:2-(:3二醇, 如:乙二醇或1,3-丙二醇,或糠基醇或四氫糠基醇。雙極 性非質子性溶劑包括如:二曱基曱醯胺、N -甲基吡咯烷 酮、二甲亞楓、乙腈、環丁楓、石肖基甲烧等等溶劑。較佳 極性溶劑為水溶性有機羧酸、醇或0-單取代之單或聚乙二 醇,例如:乙酸、曱醇或乙二醇單曱醚,以乙酸特別佳。 極性溶劑可直接使用或與水混合使用。Such as: acetic acid or propionic acid, or alcohol, such as: sterol, ethanol, propanol, or 0-: monosubstituted mono or oligoethylene glycol, such as: ethylene glycol monomethyl ether or (: 2- (: 3 a diol such as ethylene glycol or 1,3-propanediol, or a mercapto alcohol or a tetrahydrofurfuryl alcohol. Bipolar aprotic solvents include, for example, dimethyl decylamine, N-methylpyrrolidone, dimethyl Solvents such as arsenic, acetonitrile, cyclobutyl sulphate, succinyl or the like. Preferred polar solvents are water-soluble organic carboxylic acids, alcohols or 0-monosubstituted mono- or polyethylene glycols, such as acetic acid, decyl alcohol or ethylene glycol. Alcohol monoterpene ether, especially preferably acetic acid. Polar solvents can be used directly or mixed with water.

第8頁 1291952 五、發明說明(6)Page 8 1291952 V. Description of invention (6)

除里丄Ξ::粗產物之非極性雜質於第一個萃取階段中排 取里ΐ = 於第二個萃取階段中排除。以極性溶U 里卜斯他丁時,即排除極二:雜…非極性-劑萃取 次ΐϊίΐίΓ”中L兩次萃取均使用相同溶劑。第- 兩相比彳丨〜、第一個步驟,其係加水稀釋極性溶劑或改肖 相比例,以改變里卜斯他丁之分佈。 κ文 極性溶』Ϊ J ί Τ ::例中’、進行第一次萃取之方式為以 中卒取里卜斯他丁,最好使用與第一步〉谷 非極性溶劑。 干% /〜相同之 =具體實施例中,第一個步驟之溶液—液體萃取法 寸徵為極性溶劑包含約}至約2〇%水,更佳者約5%水。 特::項較佳具體實施中,非極性溶劑為脂系自。以庚烷 本發明最佳具體實施例中,第一個步驟之液體_啤一 取法為雙流向萃取法,且以極性溶劑萃取里卜斯他丁。卒 料為里卜斯他丁粗產考勿,可使用其中一種溶劑稀釋 ^ 性(重)相萃取里卜斯他丁;非極性雜質如:脂肪酸或。 酯則留在非極性(輕)相。由於里卜斯他丁與雜質之分佈係 數依濃度、兩種溶劑相比例、萃取系統之理論係數,及進 料對溶劑之比例而異,因此必須依適當方式調整。TC羅 (Lo),拜爾德(Bairds), MHI, M,海菲茲(Ha fez),c 漢准森 (nanson)(1983)· /谷劑卒取法手冊(Handbook of 1291952 五、發明說明(7) extraction),紐約威利公司(WUey,心胃Y〇rk)。分佈係 數對濃度之依賴性隨萃取系統使用之極性溶劑種類強力變 $、。水性乙酸在達成高濃度上有極佳結果,因此有高度物 料通過料及使用最少量溶劑。 么進行ΐ取ί時,可使用連續萃取設備如:混合器澄清器 糸統或萃取管柱如:脈衝式篩板萃取器,或攪拌管柱。 土較佳具體實施例中,再萃取之前(第二純化步驟) 稀釋極性溶劑至約70%至90%,以約80%較佳。 本發明最佳具體實施例中,第二純化步驟之再萃 =逆流萃取法進行,並使里卜斯他丁萃取至非極^ 中。此時即可直接使用第一次萃取法之萃液。鱼需;jIn addition to the 丄Ξ:: the non-polar impurities of the crude product are removed in the first extraction stage = excluded in the second extraction stage. When the polar solution U ribastatin is used, the exclusion of the pole two: miscellaneous ... non-polar - agent extraction ΐϊ ΐϊ ΐϊ ΐϊ 中 中 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次 两次It is a method of adding polar water to dilute a polar solvent or changing the ratio of ribs to change the distribution of ribavirin. κ 极性 极性 Ϊ Ϊ Τ Τ Τ Τ Τ Τ Τ Τ Τ Τ Τ 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 Statin, preferably used in the first step > a valley non-polar solvent. Dry % / ~ the same = in the specific embodiment, the first step of the solution - liquid extraction method for the polar solvent contains about} to about 2 〇% water, more preferably about 5% water. Special:: In a preferred embodiment, the non-polar solvent is a lipid system. In the preferred embodiment of the invention, heptane, the first step of the liquid_beer One method is the double flow extraction method, and the ribastatin is extracted with a polar solvent. The crude material is ribsstatin crude, and one of the solvents can be used to dilute the (heavy) phase extract ribastatin. Non-polar impurities such as: fatty acids or esters remain in the non-polar (light) phase. The distribution coefficient of statin and impurities depends on the concentration, the ratio of the two solvents, the theoretical coefficient of the extraction system, and the ratio of the feed to the solvent, so it must be adjusted according to the appropriate method. TC Luo (Lo), Baird (Bairds) ), MHI, M, Ha fez, c nanson (1983) · / glutinous stroke method manual (Handbook of 1291952 five, invention description (7) extraction), New York Willie ( WUey, heart and stomach Y〇rk). The dependence of the distribution coefficient on the concentration is strongly changed with the type of polar solvent used in the extraction system. The aqueous acetic acid has excellent results in achieving high concentration, so there is a high amount of material passing material and the minimum amount of material used. Solvents. For extraction, a continuous extraction apparatus such as a mixer clarifier or an extraction column such as a pulsed sieve plate extractor or a stirred column may be used. In a preferred embodiment, re-extraction Previously (second purification step) dilute the polar solvent to about 70% to 90%, preferably about 80%. In a preferred embodiment of the invention, the second purification step is re-extracted = countercurrent extraction, and Bustastat extraction into non-polar ^ At this time, it can be used directly for the first time extraction fish extracts required;. J

J里卜斯他丁進料之雙流向萃取法相&,若以連續式K 卞取法進行第二次萃取時,在第一次萃兩 /;,L 卜斯他丁。里卜斯他丁被萃取至非極性(輕里 質則留在極性(重)相。 …相而極性雜 =酵期間會形成里卜斯他丁之數種胺基酸類似物。 丁本身包含n_曱醯基)白胺酸作為側鏈,而副產物 2含其他N-甲醢基胺基酸。其中一種副產物為類;以產物 =之里卜斯他丁。里卜斯他丁粗產物中此副產物:: J相對於里卜斯他丁之3%。純化"斯他丁 :: 乍法非常重要。否則接續之氫化作用將 ::; 若里"卜斯他丁粗產物中類似甲硫胺酸之; 斯他丁粗產物之純化法。除非在氧化成相應之亞^卜The double flow direction extraction method & J ribsstatin feed, if the second extraction is carried out by the continuous K extraction method, the first extraction of two /;, L bustin. Ribsstatin is extracted to a non-polar (light lining remains in the polar (heavy) phase. ... phase and polar miscellaneous = several amino acid analogs of ribastatin are formed during leaven. N_mercapto) leucine as a side chain and by-product 2 contains other N-methyl mercapto amino acids. One of the by-products is a class; the product = ribavirin. This by-product of the crude product of ribastatin: J is 3% relative to ribsstatin. Purification "statin :: The method is very important. Otherwise, the subsequent hydrogenation will be similar to the methyl methionine in the crude product of the ruthenium; the purification of the crude statin. Unless it is oxidized into the corresponding

O:\62\62173.PTD 第10頁 1291952 I五、發明說明(8) i後,否則無法直接利用結晶法或萃取法排除類似甲硫胺酸 I之里卜斯他丁來純化里卜斯他丁。此氧化法係依習知方法 I進行,例如:於乙酸中使用過乙酸。類似曱硫胺酸之里卜 丨斯他丁可氧化成亞楓或碾:O:\62\62173.PTD Page 10 1291952 I I. Description of invention (8) i, otherwise it is not possible to directly use crystallization or extraction to exclude ribavirin similar to methionine I to purify Ribs He Ding. This oxidation process is carried out according to conventional method I, for example, by using peracetic acid in acetic acid. Similar to 曱 曱 曱 丨 丨 丨 丨 可 可 可 可 氧化 氧化 氧化 氧化 氧化 氧化 氧化 氧化 氧化

CH,C0-0-0H 〇=s=〇CH, C0-0-0H 〇=s=〇

若需氧化成亞楓時,氧化劑用量為類似甲硫胺酸之里卜 斯他丁之等莫耳量或至高1. 5當量,若需氧化成楓時,則 使用2倍量。應避免大量過量,以防止里卜斯他丁氧化分 解。氧化法係於0 °至50 °C下進行,以室溫下較佳;反應 在數分鐘内完成。氧化法採用之溶劑並不重要,萃取純化 法中採用之溶劑之一最好亦用於氧化法。類似甲硫胺酸之 里卜斯他丁可在里卜斯他丁粗產物步驟氧化或在第一次萃 取步驟之後氧化。氧化法最好使用含高濃度里卜斯他丁粗 產物之庚烷溶液進行,所得混合物則用為第一次萃取純化If it is desired to oxidize to yam, the amount of the oxidizing agent is erbene-like methionine or the molar amount of 1. 5 equivalents, and if it is to be oxidized into maple, it is used twice. A large excess should be avoided to prevent oxidative decomposition of ribavirin. The oxidation process is carried out at 0 ° to 50 ° C, preferably at room temperature; the reaction is completed in a few minutes. The solvent used in the oxidation method is not critical, and one of the solvents used in the extraction purification method is preferably used in the oxidation method. Ribastatin, which is similar to methionine, can be oxidized in the crude ribastatin step or after the first extraction step. The oxidation method is preferably carried out using a heptane solution containing a high concentration of the crude ribavirin, and the resulting mixture is used for the first extraction and purification.

第11頁 1291952Page 11 1291952

I 五、發明說明(9) 步驟之進料。氧化後 j 1雜質,在第二次萃取 ! 若萃取純化法使用 I後,直接使用第一次 法即足以作為第二次 !之類似曱硫胺酸之里 丨在最佳具體實施例中 i他丁之方法為以雙流 I 95%乙酸/庚烷中,然 |乙酸,及以庚烷逆流 丨自庚烷中單離純化之 中: 水性乙酸一^ I卜斯他丁粗產物 (含甲硫胺酸之 一^-副產物氧化後) 庚烷 之類似甲硫胺酸之里卜 法中留在極性相中排除 水性乙酸/庚烷系統時 萃取步驟得到之萃液進 萃取步驟,因為里卜斯 卜斯他丁之間之分佈係 ’自里卜斯他丁粗產物 向萃取法萃取里卜斯他 後加水稀釋里卜斯他丁 萃取溶液。然後利用濃 里卜斯他丁。,此較佳方 庚烷十非極性雜質 第一次萃取 斯他丁為極性 〇 ,以在加水 行之逆流萃取 他丁與氧化後 數不同。因此 中純化里卜斯 丁粗產物至約 溶液至約8 0 % 縮或結晶法, 法說明於下圖 含衿庚烷中之純化 之里卜斯他丁 I----► 乙酸中 丁+極性 於水性 ▲ 水 第二次萃取 庚烧-► 水性乙酸+極性雜質I V. Description of invention (9) Feed of the steps. After the oxidation of the j 1 impurity, in the second extraction! If the extraction purification method uses I, the first method is used directly as a second! Similar to the thiol amide in the best embodiment i The method of dicing is to separate and purify from heptane by double-flow I 95% acetic acid/heptane, then acetic acid, and counter-current heptane from heptane: Aqueous acetic acid-I-Busstatin crude product (including A One of the thioacids is oxidized by a by-product. The heptane is similar to the methionine in the polar phase. The aqueous solution is removed from the aqueous acetic acid/heptane system. The distribution between busbutatin is 'distilled from the crude product of ribavirin to the extraction method and dilute the ribavirin extraction solution with water. Then use concentrated ribastatin. This preferred heptane ten non-polar impurity is the first extraction of statin as a polar 〇 to countercurrent extraction in the addition of water. Therefore, the crude product of Ribstin is purified to about 80% reduction or crystallization. The method is illustrated in the following figure. The purified ribastatin I---- Polarity in water ▲ Water second extraction Geng burning - ► Aqueous acetic acid + polar impurities

第12頁 I29l952 I五、發明說明(10) 1 如上已述,依上述任何方 =轉化成四氫里卜斯他丁 (’歐斯二里』:::可利用氫 本身已知之方法進行氫化里卜斯他丁可根據 :领08”之方法,於二觸:於=利案 用之觸媒實例為Pd/C,氧化nU在下進行。可使 之溶劑並不重[最佳溶 :f。氫化作用使用 此時則直接使用含里卜斯他丁之萃;後::步驟之溶劑。 :。其他合適溶劑為例如:低碳數醇類如或行氣 ,甲院。氫化作用最好在低氫氣磨下及室\\化雄谷劑如:二 本發明亦包括在上述萃取法後,氫 仃因此 笱Φ k把从丁 + 里卜斯他丁,形成四 辽里卜斯他丁。較佳者,該反應在25它及 0.5至5巴)下,使用含貴金屬之氫化觸媒進行。* (例如: =里卜斯他丁可利用結晶純化及單離。最好使用非極 生/合刮如:己烧或庚烷進行氫化及結晶。 總言之,本發明係有關如上述定義之方法,其包括: a)氧化類似甲硫胺酸之里卜斯他丁, b )以約95%乙酸/庚烷雙流向萃取里卜斯他丁粗產物, c )加水稀釋里卜斯他丁溶液至約8 〇 %乙酸;及 d)以庚烧逆流萃取溶液。 繼此過程後,可氫化里卜斯他丁形成四氫里卜斯他丁, 視需要繼續進行四氫里卜斯他丁之結晶作用。 本發明亦包括一種製備四氫里卜斯他丁之方法,其包 括:Page 12 I29l952 I V. INSTRUCTIONS (10) 1 As described above, according to any of the above = conversion to tetrahydroribastatin ('Osri"::: hydrogenation can be carried out by the method known per se by hydrogen itself Ribsstatin can be based on: the method of collar 08", in the two touch: the catalyst used in the case of the case is Pd / C, the oxidation of nU is carried out. The solvent can not be heavy [optimal solution: f At this time, hydrogenation is used directly. The solvent containing the ribavirin; the following:: solvent of the step: Other suitable solvents are, for example, low-carbon alcohols such as or gas, a hospital. The best hydrogenation Under low hydrogen milling and chambers, such as: the second invention also included in the above extraction method, the hydroquinone thus 笱 Φ k from Ding + ribastatin, forming tetraploid ribastatin. Preferably, the reaction is carried out using a hydrogenation catalyst containing a noble metal at 25 and 0.5 to 5 bar. * (For example: = ribsstatin can be purified and isolated by crystallization. It is preferred to use non-polar / squeezing such as: hydrogenation and crystallization by calcination or heptane. In summary, the invention relates to a method as defined above, which comprises : a) oxidize ribastatin similar to methionine, b) extract ibsstatin crude product with a flow of about 95% acetic acid / heptane, c) dilute ribastatin solution with water to about 8 〇% acetic acid; and d) counter-current extraction of the solution with heptane. Following this process, the hydrogenated ribastatin forms tetrahydroribastatin, and the crystallization of tetrahydroribastatin is continued as needed. The invention also includes a method of preparing tetrahydroribastatin comprising:

第13頁Page 13

1291952 五、發明說明(11) a) 氧化類似甲硫胺酸之里卜斯他丁 b) 以約95%乙酸/庚烷雙流向萃取里卜斯他丁粗產物; c )加水稀釋里卜斯他丁溶液至約8 〇 %乙酸;及 d) 以庚烷逆流萃取溶液,然後 e) 氫化里卜斯他丁形成四氫里卜斯他丁。 此外’本發明係有關以上述方法製備里卜斯他丁及四氫 里卜斯他丁之用途。 下列實例將說明本發明較佳具體實施例,但並未限制本 發明之用途。1291952 V. INSTRUCTIONS (11) a) Oxidation of ribastatin similar to methionine b) extraction of crude ribastatin by a flow of about 95% acetic acid/heptane; c) dilution of water by Ribs The butyl solution is about 8 〇% acetic acid; and d) the solution is extracted countercurrently with heptane, and then e) hydrogenated ribavirin forms tetrahydroribastatin. Further, the present invention relates to the use of the preparation of ribastatin and tetrahydroribastatin by the above method. The following examples illustrate preferred embodiments of the invention, but do not limit the use of the invention.

實例 實例1 :Example Example 1:

由來自醱酵過程經分離生質及萃取後得到之里卜斯他丁 粗產物濃縮。使用之物質含有58%(w/w)里卜斯他丁(HPLC 分析法)及0· 9%(w/w)類似甲硫胺酸之里卜斯他丁(iH —NMR 分析法)。 a ·類似里卜斯他丁之里卜斯他丁之氧化法:以7 7毫升庚烷 稀釋5 5· 7克里卜斯他丁粗產物。添加21 2微升37%過乙酸之 乙酸溶液’混合物於室溫下攪拌3〇分鐘。The crude product of ribavirin obtained by separation of the biomass from the fermentation process and extraction is concentrated. The substance used contained 58% (w/w) ribavirin (HPLC analysis) and 0.9% (w/w) ribavirin similar to methionine (iH-NMR analysis). a · Oxidation of ribastatin similar to ribastatin: Dilute 5 5.7 bristastine crude product with 7 7 ml of heptane. 21 2 μl of 37% peracetic acid in acetic acid solution was added. The mixture was stirred at room temperature for 3 minutes.

b .以庚烧/9 5%乙酸水溶液進行雙流向萃取:為了模擬具有7 個分離階段之萃取器,採用7支分離漏斗。 由a項說明之氧化法得到之混合物分成6份,每一份均自 第4支分離漏斗(s f -4 )送入。由s f _ 4進料開始,添加5 〇毫 升庚炫及100毫升95%水性乙酸,相當於庚烧/水性乙酸之 相比例為1 /2。混合物振盪,分層。上層移至下一支分離b. Double flow extraction with heptane/9 5% aqueous acetic acid: To simulate an extractor with 7 separation stages, 7 separation funnels were used. The mixture obtained by the oxidation method described in item a was divided into 6 portions, each of which was fed from the fourth separation funnel (s f -4 ). Starting from the s f _ 4 feed, 5 〇 liters of heptane and 100 ml of 95% aqueous acetic acid were added, which corresponds to a ratio of 1 /2 for the heptane/aqueous acetic acid. The mixture was shaken and layered. Move the upper layer to the next separation

第14頁 1291952 五、發明說明(12) 漏斗,下層則移至上一支分離漏斗-剛開始時,使用新鮮 溶劑,然後逐步被來自上一支及下一支分離漏斗之溶劑相 置換。當依此方式填充過所有分離漏斗後’在第一支分離 漏斗中添加庚院,只在第7支分離漏斗中添加水性乙酸。 收集含里卜斯他丁之萃液。利用薄層層析法追縱殘液中之 里卜斯他丁,使其含量保持在每升1克以下’並控制預先 計算之兩相比例與濃度。 當送入所有里卜斯他丁粗產物後,添加這二種乾淨之溶Page 14 1291952 V. INSTRUCTIONS (12) Funnel, the lower layer is moved to the previous separation funnel - at the beginning, fresh solvent is used and then gradually replaced by the solvent phase from the previous and next separation funnels. When all the separation funnels were filled in this way, 'Gengyuan was added to the first separation funnel, and only the seventh acetic acid was added to the separation funnel. Collect the extract containing ribavirin. The ribavirin in the raffinate was traced by thin layer chromatography to keep the content below 1 gram per liter' and the pre-calculated two ratios and concentrations were controlled. After feeding all the crude products of ribastatin, add these two clean dissolves.

劑’直到所有里卜斯他丁均洗出系統為止。下文說明此萃 取法: _ 庚烷 _ 庚烷+#極性 副產物(殘液) 庚烷 里卜斯他丁粗產物Agent' until all the ribsstatin is washed out of the system. This extraction method is described below: _ heptane _ heptane + #polar by-product (residual liquid) heptane ribastatin crude product

I ▼ sf-3 sf-4 sf-5 I sf-2 ◄---! 里卜斯他丁含於 水性乙酸中(萃液) sf-6 sf-7 A 95%乙酸I ▼ sf-3 sf-4 sf-5 I sf-2 ◄---! Ribastatin is contained in aqueous acetic acid (extract) sf-6 sf-7 A 95% acetic acid

95%水性乙酸μ 減壓蒸餘排除溶劑,使萃液濃縮至體積約6 〇 〇毫升。由 卡爾費雪方法測得之水含量為3.5%。 C •逆流萃取法:為了模擬具有7個分離階段之萃取器,再度 使用7支分離漏斗。95% aqueous acetic acid μ was evaporated under reduced pressure to remove the solvent, and the extract was concentrated to a volume of about 6 〇 〇. The water content measured by the Karl Fischer method was 3.5%. C • Countercurrent extraction: In order to simulate an extractor with 7 separation stages, 7 separate funnels were used again.

1291952 五、發明說明(13) 將來自b項之萃液(600毫升)分成6份(各1〇〇毫升),每份 |均與30毫升水共同加至第7支分離漏斗中。在第1支分== i斗中添加130毫升庚烷。類似b)項之連續方法模擬進77行萃 取,其係將上層移至下一支分離漏斗,將下層移至上一支 分離漏斗。利用薄層層析法追蹤殘液中里卜斯他丁,使其 含量保持在每升1克以下,以控制預先計算之兩相比例及' |濃度。當來自第一次萃取步驟之萃液均送入後,同時添加 丨二種溶劑,直到所有里卜斯他丁均洗出為止。下圖說;^ 種萃取法: e s 庚烷1291952 V. INSTRUCTIONS (13) Distillate (600 ml) from item b was divided into 6 portions (1 ml each), and each was added to the 7th separation funnel together with 30 ml of water. Add 130 ml of heptane to the first branch == i bucket. A continuous method like b) simulates the extraction of line 77, which moves the upper layer to the next separation funnel and the lower layer to the previous separation funnel. The ribavirin in the raffinate was traced by thin layer chromatography to keep the content below 1 gram per liter to control the pre-calculated two ratios and the concentration of . After the extract from the first extraction step was fed, both solvents were added until all the ribavirins were washed out. The following figure says; ^ extraction method: e s heptane

庚烷 τHeptane τ

sf-4 sf-5 sf-6 極性雒質(殘液) 含於庚烷中之 铃化之里卜斯 他丁 (萃液) 含於水性乙酸中之 里卜斯他丁 (第一次萃液)+水Sf-4 sf-5 sf-6 polar enamel (residual liquid) Ribastatin (extracted liquid) containing bellulidine in heptane. Ribastatin in aqueous acetic acid (first extract) Liquid) + water

水性乙酸 收集含於庚烷中之純里卜斯他丁(萃液),減壓濃縮至 •2 50毫升體積。此溶液包含3 5· 3克純里卜斯他丁,純度 9 0 % ( w / w ) (IIP L C )。根據純產物中里卜斯他丁含量計算,其Aqueous acetic acid The pure ribastatin (extract) contained in heptane was collected and concentrated under reduced pressure to a volume of • 2 50 ml. This solution contains 3 5 3 g of pure ribavirin with a purity of 90% (w / w) (IIP L C ). Calculated according to the content of ribastatin in the pure product,

第16頁 1291952 五、發明說明(14) |相對於粗產物中里卜斯他丁含量之收率相當於98% P d·氫化法:取250毫升純化之里卜斯他丁於不銹鋼高壓蚤 I中,於25 I及5巴壓力下,使用3· 5克5%Pd/C氫化共6小 |時。濾除觸媒,濾液蒸發。殘質溶於700毫升庚烷中,使 j四氫里卜斯他丁於Ot:下結晶。過濾產物,以冷庚院洗 I滌,於託t下真空乾燥。得到28克四氫里卜斯他丁,純度 丨9 6%(W/W)(HPLC)。相對於純產物中里卜斯他丁之收率為 丨85/。自己烧中再結晶後之四氫里卜斯他丁純度為 1 97%(w/w)(HPLC)。 又 實例2: 知用7段式混合is澄清器系統,使用與實例丨相同之溶劑 i進行連續式萃取。 所採用之辰縮之里卜斯他丁粗·產物純度為65%(w/w),其 中含0· 14%(w/w)類似曱硫胺酸之里卜斯他丁。 a.使用庚烷/95%水性乙酸進行之雙流向萃取法:以ι〇〇公 庚烷稀釋100公斤S卜斯他丁粗產物,使用此溶液作 料。在混合器澄清器中填入庚烷與95%.水性乙酸, 為1/2U/V)。進行萃取純化法時,每小時添加3? 5 烧,75升95%水性乙酸及15升里卜斯他丁粗產物溶液厌 ⑴支添加庚院’在第4支添加里卜斯他丁溶液, f 混合器添加水性乙酸。收集含量卜斯他丁之萃液支 性雜質之錄。利用薄層層析法追縱殘液中里卜 =^ 量,保持在母升1克以下。所有里卜斯他丁粗產物 3 後,繼續送入兩種溶劑,直到所有里卜斯他丁均洗出运為入Page 16 1291952 V. Description of the invention (14) | The yield of ribavirin content relative to the crude product is equivalent to 98% P d. Hydrogenation method: 250 ml of purified ribavixine in stainless steel 蚤I In the case of 25 I and 5 bar pressure, a total of 6 hours of hydrogenation was carried out using 3.5 grams of 5% Pd/C. The catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in 700 ml of heptane to crystallize the tetrahydroribastatin at Ot:. The product was filtered, washed with cold gent, and dried under vacuum at Torr. 28 g of tetrahydroribastatin was obtained with a purity of 丨9 6% (W/W) (HPLC). The yield of ribastatin relative to the pure product is 丨85/. The purity of tetrahydroribastatin after recrystallization in oneself was 1.97% (w/w) (HPLC). Further Example 2: It is known to use a 7-stage mixed is clarifier system for continuous extraction using the same solvent i as the example. The ribastatin crude product used was 65% pure (w/w), which contained 0.14% (w/w) of ribavirin similar to guanidine thioacetate. a. Double flow extraction using heptane / 95% aqueous acetic acid: 100 kg of the crude S-bisbistine was diluted with ι 〇〇 heptane and used as a solution. The mixer clarifier was filled with heptane and 95% aqueous acetic acid, 1/2 U/V). When extracting and purifying, add 3? 5 burning per hour, 75 liters of 95% aqueous acetic acid and 15 liters of ribastatin crude product solution (1) added Gengyuan' in the 4th addition of ribastatin solution, f Mixer adds aqueous acetic acid. Collect the amount of impurities contained in the extract of bustadine. Thin layer chromatography was used to trace the amount of rag in the residual liquid and keep it below 1 gram of the mother. After all the crude ribsatin 3, continue to feed the two solvents until all the ribsstatin is washed out

1291952 五、發明說明(15) 止。取一份萃液樣本(下層)濃縮,測得里卜斯他丁純度為 71%(W/W)。共得到1 500公斤萃液,含水量為4 6%(卡爾費 雪法)。 b.類似甲硫胺酸之里卜斯他丁之氧化法··添加6〇毫升37%過 乙酸之乙酸溶液至來自前一次萃取之萃液中,混合物於室 溫下攪拌30分鐘。 c·逆流萃取法:添加280升水以調整含水量至2〇%。由於加 水後使里卜斯他丁之油相分離,因此以6〇〇升庚烷萃取此 溶液。分離此萃取液,並將後者加至連續萃取之庚烷相。 為了 ~續連萃取殘留之含里卜斯他丁之水性乙酸,採用 與第:次萃取法相同之混合器澄清器。進行連續式萃取法 日守’每小時添加5 0升庚烷至第1支,每小時添加5 〇升含里 卜斯他丁之水性乙酸至第7支混合器中。取庚烷萃液加至 刖一次得到之萃液中,減壓蒸餾排除溶劑,濃縮此溶液至 約1000升體積。取樣濃縮至乾,產生純度86%(w/w)之里卜 斯他丁。 d·氫化法:所得溶液分3批等量進行氫化。於襯玻璃墊之授 拌氫化器中進行氫化。每一批使用2 kg 5%Pd/C。1小時後 完成氫化’氫氣壓達5巴。濾除觸媒,蒸餾排除溶劑溶劑 )辰縮濾液。乾燥之樣本產物含有90%(w/w)四氫里卜斯他丁 (其品質高於純化之里卜斯他丁,因為里卜斯他丁含有”可 轉化之副產物,其係位置不同或僅含一個C = C雙鍵之異構 物’其在氫化後亦轉形成四氫里卜斯他丁)。添加6 0 0公斤 庚烧’使四氫里卜斯他丁於〇。(:下結晶。濾除產物,以冷1291952 V. Description of invention (15). A sample of the extract (lower layer) was concentrated and found to have a purity of 71% (w/w) of ribavirin. A total of 1,500 kg of extract was obtained with a water content of 4 6% (Karl Fisher method). b. Oxidation of ribavirin similar to methionine. Add 6 ml of a 37% acetic acid solution of acetic acid to the extract from the previous extraction, and the mixture was stirred at room temperature for 30 minutes. c. Countercurrent extraction: Add 280 liters of water to adjust the water content to 2%. The solution was extracted with 6 liters of heptane because the oil of the ribastatin was separated after the addition of water. The extract was separated and the latter was added to the continuously extracted heptane phase. In order to continuously extract the residual aqueous ibexatin-containing acetic acid, the same mixer clarifier as the first extraction method was used. For continuous extraction, Nissho added 50 liters of heptane per hour to the first branch, and added 5 liters of aqueous acetic acid containing ribastatin to the seventh mixer per hour. The heptane extract was added to the extract obtained once, and the solvent was distilled off under reduced pressure, and the solution was concentrated to a volume of about 1000 liters. The sample was concentrated to dryness to yield ritastatin with a purity of 86% (w/w). d. Hydrogenation: The resulting solution was hydrogenated in three equal portions. Hydrogenation is carried out in a stirred hydrogenator of a lining glass mat. Use 2 kg 5% Pd/C per batch. After 1 hour, the hydrogenation was carried out to a hydrogen pressure of 5 bar. The catalyst was filtered off, and the solvent was distilled off to distill the filtrate. The dried sample product contains 90% (w/w) tetrahydroribastatin (the quality is higher than the purified ribavirin, because ribastatin contains "transformable by-products, which have different positions Or an isomer containing only one C=C double bond, which is also converted to tetrahydroribastatin after hydrogenation. Add 600 kg of Gengzhuo' to make tetrahydroribastatin to 〇. : Crystallization. Filter out the product to cool

第18頁 1291952 五、發明說明(16) 庚院洗務,減壓乾燥。 一批產生17公斤純度97%(w/w)之四氫里卜斯他丁。其相 對於里卜斯他丁粗產物中里卜斯他丁之收率相當於76%之 四氫里卜斯他丁。 * 實例3 : 自醱酵過程中分離生質及萃取後得到之里卜斯他丁粗產 物濃縮。該物質含有62%(w/w)里卜斯他丁及〇· i%(w/w)類 似甲硫胺酸之里卜斯他丁。 、 a ·類似甲硫胺酸之里卜斯他丁之氧化法:以7 5毫升庚烷稀 ,53克里卜斯他丁粗產物。添加24微升37%過乙酸之乙酸 溶液,混合物於室溫下攪拌3 〇分鐘。 ^使用庚烷/1〇%水性曱醇進行之雙流向萃取法:依實例1 用、Γ,7支分離漏斗系統模擬連續萃取法。、將來 d)項况明之軋化法之混合物分成6份, 碓漏斗送入。添加100毫升庚烷至第丨Φ +伤均自弟4支分 1叫性甲醇至第7支分離:斗中至=L 相比例相當於1 0/1。收集萃液(上層,含里^曱醇之兩 ,)。當所有里卜斯他丁粗產物均送他丁之庚 鮮溶劑,直到所有1卜斯他丁均洗"·出入為後/再添加二種新 餾排除溶劑,濃縮至丨i 0毫升體積。" 萃液經減壓蒸 c•使用庚烷/10%水性曱醇再進行雔 述萃取法之、·容液八占m又他向卒取法:將得自上 取忐之,合液刀成6伤。採用前述相同7 進什相同萃取法但兩相比例不同。 支h離漏斗系統 離漏斗中送入。添加100毫升庚燒至第=均自第4支分 支中,添加1 0 0毫%Page 18 1291952 V. Description of invention (16) Gengyuan washing, drying under reduced pressure. One batch produced 17 kg of 97% (w/w) tetrahydroribastatin. Its yield relative to ribastatin in the crude ribastatin product is equivalent to 76% tetrahydroribastatin. * Example 3: Separation of biomass from the fermentation process and concentration of the crude ribavirin obtained after extraction. This material contains 62% (w/w) ribastatin and 〇·i% (w/w) ribastatin like methionine. a. Oxidation of ribavirin similar to methionine: 7 5 ml of heptane, 53 clibetstatin crude product. 24 μl of 37% peracetic acid in acetic acid solution was added, and the mixture was stirred at room temperature for 3 minutes. ^Double-flow extraction using heptane/1% aqueous sterol: Example 1 was used to simulate continuous extraction with a seperate, 7 separation funnel system. In the future, d) the mixture of the rolling method is divided into 6 parts, and the funnel is fed. Add 100 ml of heptane to the first 丨Φ + injury from the 4th branch of the 1st to the 7th separation: the bucket to =L is equivalent to 1 0/1. Collect the extract (the upper layer, containing two of the sterols). When all the crude ribsstatin products were sent to the Dingzhi Geng fresh solvent, until all the 1 sceptin was washed "·in and out, then add two new solvent to remove the solvent and concentrate to a volume of 丨i 0 ml. " The extract is steamed under reduced pressure c. • Heptane/10% aqueous sterol is used to carry out the extraction method, and the liquid is occupied by eight occupants, and he is drawn to the method of stroke: it will be taken from the top, and the liquid knives will be obtained. Into 6 injuries. The same extraction method as described above was used, but the two comparison examples were different. The hoff funnel system is fed into the funnel. Add 100 ml of heptane to the first = all from the 4th branch, add 1 0 0%

第19頁 1291952Page 19 1291952

五、發明說明(17) 水性 例相 醇)。 鮮溶 餾溶 甲醇至第7支分離漏斗中,其庚烧/ 本认1 / Ί A在—/ 、厌況/水丨生甲醇之·兩相比 當於1/1。收集卒液(下層’含里卜斯他丁之水性甲 當所有里卜斯他丁粗產物均送入後,再添加 m所有里卜斯他丁均洗出為止。萃 劑至250毫升體積。 …、 d. 以庚烷分批萃取里卜斯他丁 :加水至得自c)項之萃液 =’,整含水量至5〇%。以各600毫升庚烧萃取此混合物2 -人。卒液經蒸餾排除溶劑濃縮。得到34克純度86%(w/w)之V. INSTRUCTIONS (17) Aqueous Examples of alcohols). Freshly soluble and dissolved in methanol to the 7th separation funnel, the heptane/recognition 1 / Ί A in - / , the situation / water methanol + two compared to 1 / 1. Collecting the stroke fluid (the lower layer of water containing ribsstatin), after all the crude ribastatin products were fed, add m and all the ribsstatin was washed out. The extract was added to a volume of 250 ml. ..., d. Extract ribastatin batchwise in heptane: add water to the extract from c) = ', the whole water content to 5〇%. The mixture was extracted with 2 g of each of 600 ml of heptane. The fluid is concentrated by distillation to remove the solvent. Obtained 34 g of purity 86% (w/w)

里卜斯他丁。根據純產物中里卜斯他丁含量計算,其相對 於粗產物中里卜斯他丁之收率相當於89%。 e. 氫化法:類似實例丨進行氫化法與結晶法。 之四氫里卜斯他丁,其相對於純產物中里卜斯他 丁之收率為9〇%。 … 實例4 : 依實例3所述,採用相同之7段式萃取裝置,純化同樣來 自實例3之里卜斯他丁粗產物。或者使用丨〇%水性乙二醇單 甲醚與庚烷作為溶劑。與實例3比較下’濃度及兩相比例 2持不變。純化後之里卜斯他丁樣本純度為8〇%(w/w)。依 前述實例進行四氫里卜斯他丁之氫化法與結晶法。得到純 度96%(w/w)之四氫里卜斯他丁。 實例5 : 方;授掉之庫尼(Kuehni)管柱上純化含里卜斯他 丁與0.6% (w/w)類似甲硫胺酸之里卜斯他丁之里卜斯他丁 粗產物。Ribsstatin. Based on the content of ribastatin in the pure product, the yield of ribavirin relative to the crude product was equivalent to 89%. e. Hydrogenation: Similar to the example of hydrazine and crystallization. The tetrahydroribastatin has a yield of 9% by weight relative to the libastatin in the pure product. Example 4: The crude ribastatin product also from Example 3 was purified using the same 7-stage extraction apparatus as described in Example 3. Alternatively, 丨〇% aqueous ethylene glycol monomethyl ether and heptane are used as a solvent. Compared with Example 3, the concentration and the two examples were unchanged. The purity of the purified ribavirin sample was 8〇% (w/w). The hydrogenation and crystallization of tetrahydroribastatin were carried out in accordance with the foregoing examples. A tetrahydroribastatin having a purity of 96% (w/w) was obtained. Example 5: square; purified ribsstatin and 0.6% (w/w) ribastatin-like ribastatin crude product on the Kuehni column .

第20頁 1291952Page 20 1291952

Claims (1)

Gang j 號 89102668 Ms 六、申請專利範圍 1. 一種自里卜斯他丁粗產物中純化里卜斯他丁 (lipstatin)之方法,其包括: a )進行液體-液體萃取法,自選自脂系或芳香系烴之 非極性溶劑中,萃取里卜斯他丁至選自羧酸、醇、0 -單取 代之單或聚乙二醇、二元醇或雙極性之非質子性溶劑之極 性溶劑中,隨後 b )加水稀釋極性溶劑相,或改變兩相比例,再萃取里 卜斯他丁至新鮮非極性溶劑中。 2 ·根據申請專利範圍第1項之方法,其中步驟a )之極性 溶劑包含約1至約2 0 %水。 、 3. 根據申請專利範圍第1或2項之方法,其中步驟a )之極 性溶劑包含約5 %水。 4. 根據申請專利範圍第1項之方法,其中非極性溶劑為 脂系烴。 5 .根據申請專利範圍第4項之方法,其中非極性溶劑為 庚烧。 6. 根據申請專利範圍第1項之方法,其中極性溶劑為水 溶性有相羧酸、醇、或〇-單取式之單或寡乙二醇。 7. 根據申請專利範圍第6項之方法,其中極性溶劑為乙 酸、甲醇或乙二醇單甲醚。 8. 根據申請專利範圍第1項之方法,其中根據申請專利 範圍第1項中步驟a)所定義之液體-液體萃取法為雙流向萃 取法,且里卜斯他丁係萃取至極性溶劑中。 9. 根據申請專利範圍第1項之方法,其中在再萃取之j No. 89102668 Ms VI. Patent Application Range 1. A method for purifying lipstatin from a crude product of ribavirin comprising: a) performing a liquid-liquid extraction method selected from a lipid system or In a non-polar solvent of an aromatic hydrocarbon, the ribastatin is extracted into a polar solvent selected from the group consisting of a carboxylic acid, an alcohol, a 0-monosubstituted mono or polyethylene glycol, a glycol or a bipolar aprotic solvent. Then b) dilute the polar solvent phase with water, or change the two ratios and extract the ribstatin into a fresh non-polar solvent. 2. The method of claim 1, wherein the polar solvent of step a) comprises from about 1 to about 20% water. 3. The method of claim 1 or 2, wherein the polar solvent of step a) comprises about 5% water. 4. The method according to item 1 of the patent application, wherein the non-polar solvent is a aliphatic hydrocarbon. 5. The method of claim 4, wherein the non-polar solvent is heptane. 6. The method of claim 1, wherein the polar solvent is a water-soluble phase carboxylic acid, an alcohol, or a mono- or mono-oligoethylene glycol. 7. The method according to claim 6, wherein the polar solvent is acetic acid, methanol or ethylene glycol monomethyl ether. 8. The method of claim 1, wherein the liquid-liquid extraction method defined in step a) of claim 1 is a dual flow extraction method, and the ribavirin is extracted into a polar solvent. . 9. According to the method of claim 1 of the scope of patent application, in which re-extraction O:\62\62173-960823.ptc 第23頁 1291952 案號 89102668 Λ_ 曰 修正 六、申請專利範圍 前,極性溶劑係加水稀釋至約9 0至約7 0 %。 1 0 .根據申請專利範圍第9項之方法,其中極性溶劑係加 水稀釋至約8 0 °/〇 1 1 .根據申請專利範圍第1項之方法,其中根據申請專利 範圍第1項中步驟b)所定義之再萃取法為逆流萃取法,且 里卜斯他丁係萃取至非極性溶劑中。 1 2 .根據申請專利範圍第1項之方法,其中里卜斯他丁粗 產物中類似甲硫胺酸之副產物在萃取前先氧化。 1 3.根據申請專利範圍第1項之方法,其隨後氫化里卜斯 他丁形成四氫里卜斯他丁。 1 4.根據申請專利範圍第1 3項之方法,其中氫化反應係 於2 5 °C及低氫氣壓下,使用含貴金屬之氫化觸媒進行。 1 5.根據申請專利範圍第1項之方法,其中 a )氧化類似甲硫胺酸之里卜斯他丁, b )以約9 5 %乙酸/庚烷雙流向萃取里卜斯他丁粗產物, c )加水稀釋里卜斯他丁溶液至約8 0 %乙酸;及 d )以庚烷逆流萃取溶液。 其隨後氫化里卜 其隨後使四氫里 其包括: 1 6 .根據申請專利範圍第1 5項之方法= 斯他丁形成四氫里卜斯他丁。 1 7.根據申請專利範圍第1 6項之方法, 卜斯他丁結晶。 斯他丁粗產物 18. —種製備四氫里卜斯他丁之方法, a)氧化類似甲硫胺酸之里卜斯他丁 b )以約9 5 %乙酸/庚烷雙流向萃取里O:\62\62173-960823.ptc Page 23 1291952 Case No. 89102668 Λ_ 曰 Amendment 6. Before applying for a patent, the polar solvent is diluted with water to about 90% to about 70%. 10. The method according to claim 9 wherein the polar solvent is diluted with water to about 80 ° / 〇 1 1 according to the method of claim 1 of the patent application, wherein step b in the first claim The re-extraction method defined is countercurrent extraction, and the ribstatin is extracted into a non-polar solvent. A method according to the first aspect of the patent application, wherein a by-product of propyl citrate similar to methionine is oxidized prior to extraction. 1 3. According to the method of claim 1 of the patent application, which subsequently hydrogenates the ribastatin to form tetrahydroribastatin. 1 4. The method according to claim 13 wherein the hydrogenation reaction is carried out at 25 ° C under a low hydrogen pressure using a hydrogenation catalyst containing a noble metal. 1 5. The method of claim 1, wherein a) oxidizing ribavirin like methionine, b) extracting crude ribastatin by a double flow of about 9.5 % acetic acid / heptane , c) diluting the ribavirin solution with water to about 80% acetic acid; and d) extracting the solution countercurrently with heptane. It is subsequently hydrogenated and subsequently subjected to tetrahydrogen including: 16. The method according to claim 15 of the patent application = statin forms tetrahydroribastatin. 1 7. Crystallization of bustastatin according to the method of claim 16 of the patent application. Stastatin crude product 18. A method for preparing tetrahydroribastatin, a) oxidizing ribastatin like methionine b) in a double flow of about 9.5 % acetic acid / heptane O:\62\62173-960823.ptc 第24頁 1291952 _案號89102668_年月曰 修正_ 六、申請專利範圍 c )加水稀釋里卜斯他丁溶液至約8 0 %乙酸;及 d )以庚烧逆流萃取溶液,隨後 e)氫化里卜斯他丁形成四氫里卜斯他丁, f )使四氫里卜斯他丁結晶。O:\62\62173-960823.ptc Page 24 1291952 _ Case No. 89102668_Yearly revision _ Six, the scope of application for patent c) Add water to dilute ribastatin solution to about 80% acetic acid; and d) The solution was refluxed to extract the solution, followed by e) hydrogenation of ribavirin to form tetrahydroribastatin, f) crystallizing tetrahydroribastatin. O:\62\62173-960823.ptc 第25頁O:\62\62173-960823.ptc Page 25
TW89102668A 2000-02-17 2000-02-17 Purification of lipstatin TWI291952B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW89102668A TWI291952B (en) 2000-02-17 2000-02-17 Purification of lipstatin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW89102668A TWI291952B (en) 2000-02-17 2000-02-17 Purification of lipstatin

Publications (1)

Publication Number Publication Date
TWI291952B true TWI291952B (en) 2008-01-01

Family

ID=45067386

Family Applications (1)

Application Number Title Priority Date Filing Date
TW89102668A TWI291952B (en) 2000-02-17 2000-02-17 Purification of lipstatin

Country Status (1)

Country Link
TW (1) TWI291952B (en)

Similar Documents

Publication Publication Date Title
EP1028115B1 (en) Purification of lipstatin
AU8950798A (en) A method for producing para-menthane-3,8-diol
EP2059493B1 (en) Recovery of phenol ligands during the production of isopulegol
FR2473519A1 (en) TERPENOIDS CONTAINING TWO FUNCTIONAL GROUPS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
CH629792A5 (en) PROCESS FOR THE PREPARATION OF NEW OXEPANE DERIVATIVES.
TWI291952B (en) Purification of lipstatin
CN107673964B (en) Process for the preparation of 2- ((5Z,8Z,11Z,14Z,17Z) -eicosa-5, 8,11,14, 17-pentaenyloxy) butanoic acid
CN114105869A (en) Preparation method of 2-propyl-4-cyanopyridine
House et al. Perhydroindan derivatives. 17. Application of the reduction-methylation sequence to 7-methoxyhexahydrofluorene derivatives
JP4183850B2 (en) Method for producing glyceryl ether
US20070135629A1 (en) Isolation of ansamitocins
US5278327A (en) Fatty oil ex helianthus annuus for the production of diperazelaic acid
Ogura et al. New synthetic route to an. alpha.-alkoxy-. alpha.-arylacetic ester using formaldehyde dimethyl dithioacetal S, S-dioxide
BE867095A (en) NEW SESQUITERPENIC DERIVATIVES USEFUL IN PARTICULAR AS INHIBITORS OF THE COMPLEMENTARY SYSTEM AND THEIR PREPARATION PROCESSES
US4008270A (en) Process for preparing 2-(substituted phenyl)propionic acids
EP1252164A1 (en) Method for producing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid
CH316155A (en) Process for the preparation of a 5-pregnene-17a,21-diol-3,11,20-trione-3,20-dialkylene-ketal
MXPA00001032A (en) Purification of lipstatin
EA015973B1 (en) Process for the selective isolation, purification and separation of monohydroxylated 3,17-diketo-steroid compounds
WO2007074062A1 (en) Method for producing an alpha-chiral chloromethyl compound in a pure form
CH648483A5 (en) PHARMACEUTICAL COMPOSITION AGAINST RHUMATOID ARTHRITIS.
CN115385818A (en) Paracetamol impurity and preparation method thereof
JPS6366302B2 (en)
DE3131524A1 (en) METHOD FOR PRODUCING PHYSIOLOGICAL EFFECTORS
SE462684B (en) NEW TRANS - EBURNAMEN DERIVATIVES AND PHARMACEUTICAL PREPARATION

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent